Your browser doesn't support javascript.
loading
Effectiveness of Apremilast in Real Life in Patients with Psoriasis: A Longitudinal Study.
Malara, Giovanna; Politi, Cristina; Trifirò, Caterina; Verduci, Chiara; D'Arrigo, Graziella; Testa, Alessandra; Tripepi, Giovanni.
Afiliação
  • Malara G; Dermatology Unit, Grande Ospedale Metropolitano Bianchi-Melacrino-Morelli, Va Vallone Petrara snc, Reggio Calabria, Italy. E-mail: Giovannamalara1@gmail.com.
Acta Derm Venereol ; 101(9): adv00545, 2021 Sep 15.
Article em En | MEDLINE | ID: mdl-34043021
Apremilast is an oral selective phosphodiesterase-4 inhibitor developed recently for psoriasis treatment. The aim of this study is to assess the real-life outcomes of use of apremilast in patients with psoriasis in everyday clinical practice. A total of 159 adult patients (90 males) with plaque psoriasis were included in the study. Fifty of the patients (31%) had psoriatic arthritis. All patients started apremilast at the time of enrolment. There was a marked improvement in Psoriasis Area and Severity Index, body surface area and Dermatology Life Quality Index scores across the follow-up period (12 months). The improvements in these scores were also consistent when the patients were stratified according to increasing body mass index. Only 10.6% of the patients discontinued apremilast, because of no response. In conclusion, apremilast is an effective and safe treatment in patients with psoriasis, and its effect is not influenced by body mass index.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Psoríase / Talidomida Tipo de estudo: Diagnostic_studies / Observational_studies Limite: Adult / Humans / Male Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Psoríase / Talidomida Tipo de estudo: Diagnostic_studies / Observational_studies Limite: Adult / Humans / Male Idioma: En Ano de publicação: 2021 Tipo de documento: Article